BRCA1 and ovarian cancer: In summary, in this study we demonstrated that SOX2 overexpression occurs in a fraction of women with BRCA1 and BRCA2 mutations prior to ovarian cancer initiation and in the majority of patients with HGSOCs irrespective of tumor stage.